Platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
Thanabalen P, Atikah S, Nurkhodrulnada ML, Roza S, Izzuna MMG
Record ID 32018002473
Authors' objectives: To assess the effectiveness, safety and cost-effectiveness of platelet rich plasma (PRP), platelet–rich fibrin (PRF) and concentrated growth factor (CGF) for periodontal therapy.
Authors' results and conclusions: Evidence demonstrated that PRP, PRF and CGF as adjunctive use for treatment of infrabony defects especially in open flap debridement and open flap debridement with bone graft were effective in reducing the pocket depth (PD) and improving the clinical attachment level (CAL) gain. There was no retrievable evidence of safety, social, ethical, legal aspects, organisational issues in the use of PRP, PRF and CGF for periodontal therapy. Cost analysis showed the estimated additional cost associated with PRF or CGF treatment ranged from RM62 to RM68 per patient per year. A decrease by at least one outpatient visit would yield an estimate of RM293 of potential cost saving per patient.
Authors' recomendations: Platelet rich plasma, platelet rich fibrin and concentrated growth factor may be used as an adjunct treatment of infrabony defects in periodontal therapy.
Authors' methods: Literature search was done to search for published articles to assess the effectiveness, safety and cost-effectiveness of platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for periodontal therapy. The following electronic databases were searched via, OVID: MEDLINE (1946 to 03 March 2021), EBM Reviews Cochrane Database of Systematic Reviews (2005 to September 29, 2021), EBM Reviews–Cochrane Clinical Answers (September 2021), EBM Reviews–Database of Abstracts of Review of Effects (1st Quarter 2016), EBM Reviews–Health Technology Assessment (4th Quarter 2016), NHS economic evaluation database (1st Quarter 2016), PubMed and INAHTA database. The last search was run on 3rd March 2021.
Authors' identified further reserach: -
Project Status: Completed
Year Published: 2021
URL for published report: https://www.moh.gov.my/index.php/database_stores/store_view_page/30/378
Requestor: Decision-making committee
English language abstract: An English language summary is available
Publication Type: Mini HTA
- Periodontal Diseases
- Platelet-Rich Plasma
- Platelet-Rich Fibrin
- Intercellular Signaling Peptides and Proteins
- Chronic Periodontitis
- Guided Tissue Regeneration, Periodontal
- Platelet rich plasma
- Platelet fibrin
- Periodontal therapy
- Concentrated growth factor
Organisation Name: Malaysian Health Technology Assessment
Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Malaysian Health Technology Assessment Section (MaHTAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.